

Proposed Project Scope

Aripiprazole for Major Depressive Disorder (MDD)

Date: March 2025

Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of aripiprazole for Major Depressive Disorder (MDD)

Table I: Policy Questions

Item	Policy Question
1	Should aripiprazole be publicly reimbursed for Major Depressive Disorder (MDD)?

Table II: Products Available in Canada

Product	Manufacturer
Aripiprazole	n/a

Project Description

Table III: Project Scope

Criteria	Description
Population	Adult patients who had an inadequate response to prior antidepressant treatments
Intervention(s)	Aripiprazole in combination with antidepressants used to treat MDD (as adjunctive treatment)
Comparators	<ul style="list-style-type: none">• Placebo• Antidepressants (monotherapy)• Other antipsychotics (e.g., Brexpiprazole, olanzapine, quetiapine, risperidone, etc.)
Outcomes	<p>Clinical effectiveness (e.g., symptom severity score rated by patients (e.g., BDI, PHQ-9, IDS-SR), symptom severity score rated by physician (e.g., HAM-D17, MADRS), function/disability measured by a validated scale (e.g., SDS), response/remission, hospitalizations for depression)</p> <p>Patient-reported outcomes (e.g., health-related quality of life)</p> <p>Safety outcomes (e.g., harms, adverse events (AEs) including AEs of particular interest [e.g., hypotension and cardiovascular AEs], serious adverse event (SAEs), discontinuations due to AEs, mortality)</p>

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of aripiprazole for MDD?
2	What are the harms associated with aripiprazole for MDD?
3	What is the expected cost of aripiprazole for MDD vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.